% | $
Quotes you view appear here for quick access.

aTyr Pharma Inc. Message Board

  • germantrader71 germantrader71 Jan 25, 2012 5:25 AM Flag


    Most Analysts expect Roche offer for ILMN to be increased

    ILMN trading above offer price in Germany

    Morgan Stanley sees Siemens under pressure to close the potential market share gap arising with Roche in Healthcare

    LIFE multiple significantly (!) below offer for ILMN

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • JP Morgan is taking price target on ILMN to $70

      "Last night, Roche (ROG VX, OW, covered by JPM analyst Alexandra Hauber)
      announced a hostile, all-cash $44.50 per share tender offer for Illumina (ILMN) that
      was described by Roche as “full and fair”. In our view, as with previous Roche hostile
      deals (including DNA, VMSI), this offer is likely a starting point, and we think it is
      highly unlikely that many investors will tender at a 44% discount to the stock’s 52-
      week high. With technology leadership and the potential for open-ended growth,
      Illumina remains an extremely attractive asset, and we think the stock is likely to
      command a larger premium; we increase our Dec 2012 price target on ILMN to $70."

3.29-0.01(-0.30%)3:37 PMEDT